Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Achaogen Awarded $18M BARDA Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

Achaogen Awarded $18M BARDA Contract

To support clinical development of antibacterial candidate for ESBL infections

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Achaogen, Inc., a late-stage biopharma company developing antibacterials addressing multi-drug resistant (MDR) gram-negative infections, has been awarded a contract valued at up to $18 million from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of C-Scape, a candidate being developed to treat serious bacterial infections. The BARDA contract includes a nine-month base period with committed funding of $12 million and subsequent option periods that, if exercised, would bring the total value of the award to $18 million.

Achaogen is conducting a Phase I trial to assess the safety, tolerability and clinical pharmacology of C-Scape, and plans for a streamlined development approach that leverages a 505(b)(2) path if the trial is successful and supports the initiation of a Phase III trial in 2018. C-Scape has been awarded Qualified Infectious Disease Product (QIDP) status by FDA for the treatment of cUTI, including acute pyelonephritis (AP). Preclinical studies have confirmed C-Scape’s potent in vitro microbiologic activity against ESBL-producing Enterobacteriaceae and its potential to achieve efficacious exposures with an oral dosing regimen.

“We are extremely grateful for BARDA’s support, and validation, of our C-Scape program as we advance this unique candidate through a streamlined development approach with an aim of initiating a pivotal Phase III trial next year,” said Kenneth Hillan, M.B. Ch.B., Achaogen’s chief executive officer. “We believe that C-Scape offers the potential for a much-needed oral therapy to effectively treat infections due to ESBL-producing Enterobacteriaceae, and we look forward to continuing to work with BARDA as they provide critical leadership in the effort to combat multi-drug resistance.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics